We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

$MLYS insiders have traded $MLYS stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales. Here’s a ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

$MLYS insiders have traded $MLYS stock on the open market 10 times in the past 6 months. Of those trades, 3 have been purchases and 7 have been sales. Here’s a ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Mineralys Therapeutics (Nasdaq: MLYS) saw its stock rise by over 40% after reporting positive top-line results from two ...

AlphaQuest LLC boosted its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 2,637.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 15,222 shares of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...